



IMRICOR COLLABORATES WITH GE HEALTHCARE

Highlights:

- Imricor and GE HealthCare have entered into a Memorandum of Understanding; with the intent to allow real-time iCMR ablations to be performed on the GE MRI platform
- A successful collaboration will enable cardiac ablation procedures, using Imricor's catheters and other disposable devices, to be performed on GE HealthCare's MRI systems
- Imricor is now collaborating with the world's three major MRI manufacturers: GE HealthCare, Siemens Healthineers, and Phillips, enabling iCMR ablations across their systems
- Imricor's new NorthStar-MR 3D Mapping System is intended to operate on the GE HealthCare MRI platform as it does on the Siemens MRI platform, offering physicians a similar user experience no matter which of the two MRI system they are operating
- Goal is to allow GE HealthCare MRI sites to participate in upcoming clinical trials

26 January 2023 – Minneapolis, MN United States (**27 January 2023** – Melbourne, Australia) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)**, the global leader in real-time iCMR cardiac ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.

Under the terms of the MOU, GE HealthCare and Imricor intend to collaborate to interface Imricor's Advantage-MR EP Recorder/Stimulator and NorthStar-MR 3D Mapping System with GE HealthCare MRI scanners. A successful collaboration will enable cardiac electrophysiology (EP) ablation procedures guided by real-time MRI, using Imricor's catheters and other disposable devices, to be performed on the GE HealthCare MRI platform. The collaboration with GE HealthCare would expand Imricor's potential to interface with GE HealthCare's new and currently installed MRI scanners.

The MOU is dated 24 January 2023 and has an initial term of five years, with automatic renewal for one year thereafter unless terminated by either party. The collaboration will involve developing hardware and software interfaces between Imricor's devices and GE HealthCare's MRI systems.

Imricor's short-term goal is to allow sites with GE HealthCare MRI systems to participate in the upcoming "**Vision-MR Ablation of Atrial FLutter**" or VISABL-AFL clinical trial in the US and "**Vision-MR Ablation of Ventricular Tachycardia**" or VISABL-VT clinical trial in Europe. The Company's overall goal is to broaden the choices physicians and hospitals have when choosing an MRI platform for their iCMR labs.

Anja Brau, PhD, General Manager, GE HealthCare MR Clinical Solutions and Research Collaborations said: *"Imricor's innovative technology has the potential to bring significant benefit to a large number of cardiac arrhythmia patients."*



“GE HealthCare has a long-standing history of applying MR to therapy guidance and control; we would be pleased to add Imricor’s capabilities to provide our customers with more options to treat their patients.”

Steve Wedan, Imricor’s CEO and Chair said: *“We are thrilled at the prospect of expanding the portfolio of MRI scanners that support Advantage-MR and NorthStar-MR technology,” “The addition of GE HealthCare will give physicians and hospitals significantly more flexibility to use the MRI hardware of their choice, when providing real-time iCMR ablations for their patients. We are grateful to our existing customers who have embraced our real-time iCMR ablation technology and look forward to making the benefits of this technology even more widely available.”*

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

Media and Investor Relations Contact:

Simon Hinsley
simon@nwrcommunications.com.au
+61 401 909 653

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor’s Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.